Glutamatergic Pharmacology
Glutamate as the major excitatory neurotransmitter, NMDA and AMPA receptor function, and drugs targeting excitatory transmission.
Glutamate Synthesis and Cycling
Glutamate is the principal excitatory neurotransmitter in the CNS. It is synthesized from glutamine by glutaminase in neurons. After release, astrocytes take up glutamate via EAAT transporters and convert it back to glutamine (the glutamate-glutamine cycle). Excess synaptic glutamate causes excitotoxicity -- neuronal death from sustained calcium influx.
Ionotropic Receptors
| Receptor | Ion Permeability | Key Features |
|---|---|---|
| NMDA | Na+, Ca2+, K+ | Voltage-dependent Mg2+ block; requires glycine co-agonist; slow kinetics |
| AMPA | Na+, K+ | Fast excitatory transmission; mediates most basal synaptic signaling |
| Kainate | Na+, K+ | Modulatory role; expressed at pre- and postsynaptic sites |
NMDA receptors are critical for synaptic plasticity (LTP) and learning. Their dual requirement for glutamate binding and membrane depolarization (to relieve Mg2+ block) makes them coincidence detectors.
Metabotropic Glutamate Receptors
Eight mGluR subtypes (mGluR1-8) are GPCRs divided into three groups:
- Group I (mGluR1, mGluR5) -- Gq-coupled, postsynaptic, excitatory
- Group II (mGluR2, mGluR3) -- Gi-coupled, presynaptic autoreceptors, reduce glutamate release
- Group III (mGluR4, mGluR6-8) -- Gi-coupled, presynaptic, inhibitory
Key Drug Classes
- NMDA antagonists -- memantine (low-affinity, uncompetitive) for Alzheimer's; ketamine (dissociative anesthetic and rapid-acting antidepressant)
- AMPA modulators -- perampanel (antagonist) is an anticonvulsant
- Glutamate release inhibitors -- riluzole reduces glutamate release; approved for ALS to slow excitotoxic motor neuron death
- Anticonvulsants -- lamotrigine inhibits voltage-gated sodium channels to reduce glutamate release
Excitotoxicity
Excessive NMDA receptor activation drives massive Ca2+ influx, activating proteases, lipases, and endonucleases that trigger cell death. This mechanism is implicated in stroke, traumatic brain injury, and neurodegenerative diseases. Neuroprotective strategies aim to reduce excitotoxicity without abolishing normal glutamatergic signaling.
Key Takeaways
- Glutamate mediates the majority of fast excitatory transmission in the brain
- NMDA receptors are coincidence detectors essential for learning and plasticity
- Excitotoxicity from excess glutamate contributes to neurodegeneration
- Memantine, ketamine, perampanel, and riluzole represent distinct glutamatergic drug strategies